| Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer MA Ghonim, SV Ibba, AF Tarhuni, Y Errami, HH Luu, MJ Dean, ... Journal for immunotherapy of cancer 9 (1), 2021 | 49 | 2021 |
| Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway MA Ghonim, J Wang, SV Ibba, HH Luu, K Pyakurel, I Benslimane, ... Journal of Translational Medicine 16, 1-12, 2018 | 19 | 2018 |
| PARP-1 is critical for recruitment of dendritic cells to the lung in a mouse model of asthma but dispensable for their differentiation and function LC Echeverri Tirado, MA Ghonim, J Wang, AA Al-Khami, ... Mediators of Inflammation 2019, 2019 | 18 | 2019 |
| Minocycline-based metronomic therapy as a novel approach to enhance anti-tumor immune responses and reduce tumor burden in mouse models of colorectal cancer SV Ibba, HH Luu, M Ghonim, C Vittori, MJ Dean, G Monticone, F Peruzzi, ... Cancer Research 82 (12_Supplement), 4211-4211, 2022 | 2 | 2022 |
| Differential effects of poly (ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells SV Ibba, HH Luu, AH Boulares American Journal of Translational Research 14 (12), 9025, 2022 | 2 | 2022 |
| The catalytic subunit of DNA-PK has a unique function in inflammation independently of Ku70 and DNA repair: a new opportunity to target the enzyme without interfering with DNA … MA Ghonim, K Pyakurel, H Luu, S Okpechi, J Ju, H Boulares The Journal of Immunology 200 (1_Supplement), 173.18-173.18, 2018 | 2 | 2018 |
| Promotion of a synthetic degradation of activated STAT6 by PARP-1 inhibition: roles of poly (ADP-ribosyl) ation, calpains and autophagy J Wang, MA Ghonim, SV Ibba, HH Luu, Y Aydin, PA Greer, AH Boulares Journal of Translational Medicine 20 (1), 521, 2022 | 1 | 2022 |
| Low Doses of PARP Inhibitors As A novel Therapeutic Approach to Enhance The Anti‐Cancer Immunotherapy of PD‐1 Immune Checkpoint Blockade MA Ghonim, A Tarhuni, H Luu, M Dean, A Al‐khami, A Ochoa, H Boulares The FASEB Journal 33 (S1), 680.15-680.15, 2019 | 1 | 2019 |
| Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer F Hossain, DA Ucar, G Monticone, Y Ran, S Majumder, K Larter, H Luu, ... Frontiers in Immunology 14, 1244159, 2023 | | 2023 |
| Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer SV Ibba, M Ghonim, A Tarhuni, M Dean, H Boulares, A Ochoa, Y Errami, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Poly (ADP) Ribose Polymerase inhibition by gene knockout or pharmacologically by olaparib restores steroid sensitivity in murine model of steroid-resistant Asthma MA Ghonim, J Wang, SV Ibba, H Luu, H Boulares The Journal of Immunology 202 (1_Supplement), 119.9-119.9, 2019 | | 2019 |
| Research Article PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function LCE Tirado, MA Ghonim, J Wang, AA Al-Khami, D Wyczechowska, ... | | 2019 |
| DNA‐PK Is Activated in Human Atherosclerotic Plaques And Its Partial Inhibition by Gene Heterozygosity Reduces Atherogenesis in Mouse Model of The Disease MA Ghonim, K Pyakurel, H Luu, M Dean, H Bazan, H Boulares The FASEB Journal 32, 570.2-570.2, 2018 | | 2018 |
